Outset Medical Faces Securities Fraud Investigation Over Misleading FDA Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: PRnewswire
- Legal Investigation Initiated: Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Outset Medical, Inc. regarding false statements about FDA clearance requirements for its key products, which could lead to significant investor losses.
- Lawsuit Progress: U.S. District Judge Edward J. Davila has ruled that key claims in a securities fraud lawsuit against Outset Medical and its executives will proceed, indicating the court's serious consideration of the case.
- Insider Trading Concerns: During the period from September 2020 to August 2024, company insiders sold over $50 million in stock, suggesting potential misconduct and raising further concerns about corporate governance.
- Stock Price Plunge Impact: Following the disappointing Q2 2024 results released in August 2024, the stock price plummeted by 68%, reflecting severe market concerns regarding the company's financial health and potentially diminishing investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OM
Wall Street analysts forecast OM stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.080
Low
7.00
Averages
11.75
High
17.00
Current: 5.080
Low
7.00
Averages
11.75
High
17.00
About OM
Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Outset Medical Faces Securities Fraud Investigation Over Misleading FDA Claims
- Legal Investigation Initiated: Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Outset Medical, Inc. regarding false statements about FDA clearance requirements for its key products, which could lead to significant investor losses.
- Lawsuit Progress: U.S. District Judge Edward J. Davila has ruled that key claims in a securities fraud lawsuit against Outset Medical and its executives will proceed, indicating the court's serious consideration of the case.
- Insider Trading Concerns: During the period from September 2020 to August 2024, company insiders sold over $50 million in stock, suggesting potential misconduct and raising further concerns about corporate governance.
- Stock Price Plunge Impact: Following the disappointing Q2 2024 results released in August 2024, the stock price plummeted by 68%, reflecting severe market concerns regarding the company's financial health and potentially diminishing investor confidence.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Outset Medical Shares Surge 25.6% on HCA Deal
- Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
- Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
- Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
- Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
See More
Osisko Metals Annual Meeting Results Announced
- Shareholder Meeting Voting: At today's annual meeting, a total of 475,369,374 common shares were represented, accounting for approximately 64.4% of the total issued shares, with all proposals approved, indicating strong shareholder support for the management.
- Auditor Appointment: PricewaterhouseCoopers LLP was appointed as the auditor for the upcoming year, with the board authorized to determine their remuneration, ensuring financial transparency and compliance for the corporation.
- Board Election Results: All management nominees were successfully elected to the board with support rates as high as 99.97%, reflecting shareholder trust in the current management team and facilitating the smooth implementation of the company's strategic initiatives.
- New Director Addition: Keith McKay was elected as a director, bringing over 30 years of financial management experience, and his extensive industry knowledge is expected to significantly support the company's expansion in the copper and zinc sectors, enhancing its competitive edge.
See More
Outset Medical (OM) Q4 2025 Earnings Transcript
See More
Outset Medical (OM) Q1 2026 Earnings Transcript
See More
Outset Medical Faces Securities Fraud Investigation Over Misleading FDA Claims
- Legal Investigation Initiated: Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Outset Medical, Inc. regarding false statements about FDA clearance requirements for its key products, which could lead to significant investor losses.
- Lawsuit Progress: U.S. District Judge Edward J. Davila has ruled that key claims in a securities fraud lawsuit against Outset Medical and its executives will proceed, indicating the court's serious consideration of the case.
- Insider Trading Concerns: During the period from September 2020 to August 2024, company insiders sold over $50 million in stock, suggesting potential misconduct and raising further concerns about corporate governance.
- Stock Price Plunge Impact: Following the disappointing Q2 2024 results released in August 2024, the stock price plummeted by 68%, reflecting severe market concerns regarding the company's financial health and potentially diminishing investor confidence.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Outset Medical Shares Surge 25.6% on HCA Deal
- Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
- Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
- Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
- Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
See More
Osisko Metals Annual Meeting Results Announced
- Shareholder Meeting Voting: At today's annual meeting, a total of 475,369,374 common shares were represented, accounting for approximately 64.4% of the total issued shares, with all proposals approved, indicating strong shareholder support for the management.
- Auditor Appointment: PricewaterhouseCoopers LLP was appointed as the auditor for the upcoming year, with the board authorized to determine their remuneration, ensuring financial transparency and compliance for the corporation.
- Board Election Results: All management nominees were successfully elected to the board with support rates as high as 99.97%, reflecting shareholder trust in the current management team and facilitating the smooth implementation of the company's strategic initiatives.
- New Director Addition: Keith McKay was elected as a director, bringing over 30 years of financial management experience, and his extensive industry knowledge is expected to significantly support the company's expansion in the copper and zinc sectors, enhancing its competitive edge.
See More
Outset Medical (OM) Q4 2025 Earnings Transcript
See More
Outset Medical (OM) Q1 2026 Earnings Transcript
See More
